These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36173630)

  • 1. Association of Oncologist Participation in Medicare's Oncology Care Model With Patient Receipt of Novel Cancer Therapies.
    Manz CR; Tramontano AC; Uno H; Parikh RB; Bekelman JE; Schrag D
    JAMA Netw Open; 2022 Sep; 5(9):e2234161. PubMed ID: 36173630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Participation in the Oncology Care Model With Medicare Payments, Utilization, Care Delivery, and Quality Outcomes.
    Keating NL; Jhatakia S; Brooks GA; Tripp AS; Cintina I; Landrum MB; Zheng Q; Christian TJ; Glass R; Hsu VD; Kummet CM; Woodman S; Simon C; Hassol A;
    JAMA; 2021 Nov; 326(18):1829-1839. PubMed ID: 34751709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Practice Patterns Among Oncologists Participating in the Oncology Care Model.
    Walker B; Frytak J; Hayes J; Neubauer M; Robert N; Wilfong L
    JAMA Netw Open; 2020 May; 3(5):e205165. PubMed ID: 32421185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Physicians Participating in Medicare's Oncology Care Model Bundled Payment Program.
    Parikh RB; Bekelman JE; Huang Q; Martinez JR; Emanuel EJ; Navathe AS
    J Oncol Pract; 2019 Oct; 15(10):e897-e905. PubMed ID: 31393806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Participation in Medicare's Oncology Care Model With Spending, Utilization, and Quality Outcomes Among Commercially Insured and Medicare Advantage Members.
    Mullangi S; Ukert B; Devries A; Debono D; Santos J; Fisch MJ; Schleicher SM; Navathe AS; Bekelman JE; Schwartz AL; Parikh RB
    J Clin Oncol; 2024 Oct; ():JCO2400502. PubMed ID: 39356984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practice patterns among oncologists participating in the oncology care model after three years.
    Walker B; Wilfong L; Frytak J; Robert N
    J Cancer Policy; 2021 Sep; 29():100294. PubMed ID: 35559949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the Impact of Oncology Care Model Reporting Requirements on Biomarker Testing and Treatment.
    Castellanos EH; Orlando A; Ma X; Parikh RB; O'Connell G; Meropol NJ; Hamrick J; Adamson BJS
    JCO Oncol Pract; 2020 Oct; 16(10):e1216-e1221. PubMed ID: 32496874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a Novel Network-Based Linchpin Score to Characterize Accessibility to the Oncology Physician Workforce in the United States.
    Moen EL; Brooks GA; O'Malley AJ; Schaefer A; Carlos HA; Onega T
    JAMA Netw Open; 2022 Dec; 5(12):e2245995. PubMed ID: 36525275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practice radiation patterns among oncologists in the Oncology Care Model.
    Walker B; Kavadi V; Wilfong L; Robert N
    Am J Manag Care; 2022 Oct; 28(10):515-519. PubMed ID: 36252170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Biosimilar Use on Total Cost of Care and Provider Financial Performance in the Medicare Oncology Care Model: A Population-Based Simulation Study.
    Yang J; Chaudhry BI; Yue AT; Roth JA; Kelton JM; Shelbaya A; Tran L; Li M
    Adv Ther; 2024 Jan; 41(1):349-363. PubMed ID: 37957523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of care for dual eligible beneficiaries in the oncology care model.
    Liang X; Zhu Z; Faraj K; Shahinian VB; Hollenbeck BK; Herrel LA
    Cancer Med; 2024 Jul; 13(14):e70009. PubMed ID: 39030893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating oncologist variability in prescribing systemic cancer therapies to patients in the last 30 days of life.
    George LS; Duberstein PR; Keating NL; Bates B; Bhagianadh D; Lin H; Saraiya B; Goel S; Akincigil A
    Cancer; 2024 Nov; 130(21):3757-3767. PubMed ID: 39077884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Greater Spending Associated with Improved Survival for Some Cancers in OCM-Defined Episodes.
    Baumgardner J; Shahabi A; Linthicum M; Vine S; Zacker C; Lakdawalla D
    J Manag Care Spec Pharm; 2018 Jun; 24(6):504-513. PubMed ID: 29799330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health care resource utilization, quality metrics, and costs of bladder cancer within the Oncology Care Model.
    Wirtz HS; Hepp Z; Grewal S; Wright P; Fuldeore R; Tomicki S; Hirsch J; Dieguez G; Blakely LJ
    Am J Manag Care; 2023 May; 29(5):e136-e142. PubMed ID: 37229787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing Medicare's Approach To Covering New Drugs In Bundled Payments For Oncology.
    Muldoon LD; Pelizzari PM; Lang KA; Vandigo J; Pyenson BS
    Health Aff (Millwood); 2018 May; 37(5):743-750. PubMed ID: 29733731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of the Oncology Care Model With Value-Based Changes in Use of Radiation Therapy.
    Kapadia NS; Brooks GA; Landrum MB; Riedel L; Liu PH; Hassol A; Tripp AS; Jhatakia S; Kummet CM; Keating NL
    Int J Radiat Oncol Biol Phys; 2022 Sep; 114(1):39-46. PubMed ID: 35150787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in Management of Coronary Artery Disease in Patients With Medicare Advantage vs Traditional Fee-for-Service Medicare Among Cardiology Practices.
    Figueroa JF; Blumenthal DM; Feyman Y; Frakt AB; Turchin A; Doros G; Gao Q; Song Y; Joynt Maddox KE
    JAMA Cardiol; 2019 Mar; 4(3):265-271. PubMed ID: 30785590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor Analysis of Health Care Access With Ovarian Cancer Surgery and Gynecologic Oncologist Consultation.
    Gupta A; Chen Q; Wilson LE; Huang B; Pisu M; Liang M; Previs RA; Moss HA; Ward KC; Schymura MJ; Berchuck A; Akinyemiju TF
    JAMA Netw Open; 2023 Feb; 6(2):e2254595. PubMed ID: 36723938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoption of Innovative Therapies Across Oncology Practices-Evidence From Immunotherapy.
    Carroll CE; Landrum MB; Wright AA; Keating NL
    JAMA Oncol; 2023 Mar; 9(3):324-333. PubMed ID: 36602811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study.
    Mitchell AP; Dusetzina SB; Mishra Meza A; Trivedi NU; Bach PB; Winn AN
    BMJ; 2023 Oct; 383():e075512. PubMed ID: 37879723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.